Abbreviation
|
Definition
|
H2AX |
Phosphorylated histone H2A member X |
ABCB1 |
ATP Binding Cassette Subfamily B Member 1 |
ALC1 |
Amplified in liver cancer protein 1 |
APLF |
Aprataxin and PNKP like factor |
APTX |
Aprataxin |
ATM |
Ataxia telangiectasia mutated |
ATR |
Ataxia telangiectasia and Rad3 related |
BARD1 |
BRCA associated ring domain 1 |
BER |
Base excision repair |
BID |
Twice a day |
BRCA1 |
Breast cancer 1 |
BRCA2 |
Breast cancer 2 |
CHK1 |
Checkpoint kinase 1 |
CSCs |
Cancer stem cells |
DDR |
DNA damage response |
DSB |
double-strand break |
DSD |
Double-strand breaks |
FDA |
Food and Drug Administration |
GIS |
Genomic instability score |
HER2 |
Human epidermal growth factor receptor 2 |
HGSOC |
High grade serous ovarian cancer |
HR |
Homologous recombination |
LOH |
Loss of heterozygosity |
LST |
Large-scale State Transitions |
MDR1 |
Multidrug resistance 1 |
MMR |
Mismatch repair |
MSI |
Microsatellite instability |
NAD |
Nicotinamide adenine dinucleotide |
NER |
Nucleotide excision repair |
NHEJ |
HR and non-homologous end-joining |
NuRD |
Nucleosome remodeling deacetylase |
PARG |
Poly (ADP) ribose glycohydrolase |
PARP |
Poly (ADP–ribose) polymerase |
PARP1 |
Poly (ADP–ribose) polymerase 1 |
PARP2 |
Poly (ADP–ribose) polymerase 2 |
PARP3 |
Poly (ADP–ribose) polymerase 3 |
PARPi |
Poly (ADP–ribose) polymerase inhibitors |
PFS |
Progression free survival |
PNKP |
Polynucleotide kinase-phosphatase enzyme |
RAD51 |
RAD51 recombinase |
RAD51C |
RAD51 recombinase C |
RAD51D |
RAD51 recombinase D |
RCA |
Replication Comb Assay |
SEER |
Surveillance, Epidemiology, and End Results |
SGO |
Society for Gynecologic Oncology |
SigMA |
signature multivariate analysis |
SSB |
Single-strand breaks |
TAI |
Telomeric Allelic Imbalance |
TMB |
Tumor mutation burden |
XRCC1 |
X-ray repair cross-complementing 1 |